MX2009011681A - Formulaciones de ziprasidona. - Google Patents

Formulaciones de ziprasidona.

Info

Publication number
MX2009011681A
MX2009011681A MX2009011681A MX2009011681A MX2009011681A MX 2009011681 A MX2009011681 A MX 2009011681A MX 2009011681 A MX2009011681 A MX 2009011681A MX 2009011681 A MX2009011681 A MX 2009011681A MX 2009011681 A MX2009011681 A MX 2009011681A
Authority
MX
Mexico
Prior art keywords
formulation
mixtures
acids
ziprasidone
optionally free
Prior art date
Application number
MX2009011681A
Other languages
English (en)
Inventor
Nageswara R Palepu
Bhanu Teja Bulusu
Original Assignee
Scidose Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scidose Llc filed Critical Scidose Llc
Publication of MX2009011681A publication Critical patent/MX2009011681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación de ziprasidona que contiene por lo menos (a) un compuesto de ziprasidona y por lo menos un componente excipiente (b) que incluye por lo menos (i) uno o más de uno mono-, di-, o tri-éster de ácidos grasos C12-24 y glicerol, en el que cada grupo de ácido graso es independientemente seleccionado de los otros, o mezclas de los mismos; y/o (ii) uno o más mono- o di-ésteres de ácidos grasos de C12-24 y poliC2-3alquileglicol, en el que cada grupo de ácido graso es seleccionado de manera independiente de los otros, o mezclas de los mismos; y/o (iii) un TPGS (polietilenglicol-ácido succínico-tocoferol); y en donde este componente (b) puede opcionalmente incluir (iv) poliC2-3alquileglicol; (v) glicerol opcionalmente libre; (vi) ácidos grasos opcionalmente libres que tienen 12-24 átomos de carbono; y (vii) mezclas de los mismos; la formulación además comprende (c) por lo menos un agente tensoactivo seleccionado de agentes tensoactivos aniónicos y no jónicos y todavía además comprende (d) por lo menos un hidroxialquil alquilcelulosa en el que cada grupo alquilo y cada grupo hidroxialquilo tiene, de forma independiente, de 1 a 4 átomos de carbono. La formulación logra disolución mejorada y bio-disponibilidad de la formulación. La reducción en el perfil de los efectos secundarios y eficacia incrementada y utilidad en indicaciones adicionales también se describe.
MX2009011681A 2007-05-18 2008-05-16 Formulaciones de ziprasidona. MX2009011681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93082407P 2007-05-18 2007-05-18
PCT/US2008/006268 WO2008143960A1 (en) 2007-05-18 2008-05-16 Ziprasidone formulations

Publications (1)

Publication Number Publication Date
MX2009011681A true MX2009011681A (es) 2009-11-10

Family

ID=40027749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011681A MX2009011681A (es) 2007-05-18 2008-05-16 Formulaciones de ziprasidona.

Country Status (10)

Country Link
US (1) US20080286373A1 (es)
EP (1) EP2146577A1 (es)
JP (1) JP2010527925A (es)
KR (1) KR20100017109A (es)
CN (1) CN101677568A (es)
AU (1) AU2008254957A1 (es)
CA (1) CA2683276A1 (es)
IL (1) IL201710A0 (es)
MX (1) MX2009011681A (es)
WO (1) WO2008143960A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0514753A (pt) * 2004-08-31 2008-06-24 Pfizer Prod Inc formas de dosagem farmacêutica compreendendo um medicamento de baixa solubilidade e um polìmero
KR20160029866A (ko) * 2007-05-25 2016-03-15 더 유니버시티 오브 브리티쉬 콜롬비아 치료제의 경구 투여를 위한 제제 및 관련 방법
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2011050457A1 (en) * 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
RU2720680C2 (ru) 2014-06-18 2020-05-12 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция, содержащая неионные сурфактанты
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
CN106880612A (zh) * 2017-02-14 2017-06-23 万全万特制药（厦门）有限公司 盐酸齐拉西酮口崩片及其制备方法
GB201904771D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
ES2210450T3 (es) * 1996-02-13 2004-07-01 Pfizer Inc. Profarmacos de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
AU730856C (en) * 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
TW200526221A (en) * 2003-09-02 2005-08-16 Imran Ahmed Sustained release dosage forms of ziprasidone
CN1898236A (zh) * 2003-10-24 2007-01-17 特瓦制药工业有限公司 制备齐拉西酮的方法
CA2550485A1 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
JP2010527925A (ja) 2010-08-19
EP2146577A1 (en) 2010-01-27
CA2683276A1 (en) 2008-11-27
IL201710A0 (en) 2010-05-31
WO2008143960A1 (en) 2008-11-27
AU2008254957A1 (en) 2008-11-27
US20080286373A1 (en) 2008-11-20
KR20100017109A (ko) 2010-02-16
CN101677568A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
MX2009011681A (es) Formulaciones de ziprasidona.
ES2209484T3 (es) Preparacion de aceite espumante y su uso.
HK1096241A2 (en) Skin lightening compositions
WO2010118926A3 (de) Verwendung organomodifizierter, im siliconteil verzweigter siloxane zur herstellung kosmetischer oder pharmazeutischer zusammensetzungen
MX2009013810A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos.
WO2013178701A3 (de) Zusammensetzungen enthaltend fettalkohole, kationische tenside und n-acyl-n-methylglucamine
PH12014500367A1 (en) Alkyl lactyllactates and processes of making the same
WO2012171850A3 (en) Cosmetic composition comprising an anionic surfactant, a nonionic or amphoteric surfactant and a solid fatty alcohol, and cosmetic treatment process
WO2003032933A8 (de) Kosmetische und/oder pharmazeutische rückfettende zubereitungen
MX2010001558A (es) Preparacion de sulfato de alcohol graso altamente concentrado.
WO2009077495A3 (en) Fatty acyl isethionate product-containing liquid cleansing compositions stabilized with mixture of long chain and short chain fatty acids/fatty soaps
WO2010108756A3 (de) Wässrige haar- und hautreinigungszusammensetzungen
WO2008019891A3 (en) Microemulsions and their use for improving the biological efficacy of pesticides
WO2013092210A3 (de) Färbemittel mit direktziehenden farbstoffen und nichtionischen tensiden
BR0211590A (pt) Composições de barra de limpeza
SI1407763T1 (sl) Sestavki, ki vsebujejo kozmeticno aktivno organsko kislino in zelenjavni produkt
WO2008126558A1 (ja) パール光沢組成物
MX2019010037A (es) Composiciones espumables para limpieza.
MX2018005786A (es) Formulaciones novedosas.
WO2006103638A3 (en) Topical pharmaceutical compositions of terbinafine and processes for their preparation
MX339685B (es) Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.
BRPI0711425A8 (pt) composições compreendendo tensoativos polimerizados de baixo dp e métodos de uso destas
JP5089196B2 (ja) 半固形状洗顔剤用組成物
WO2008144355A3 (en) Stable, self-microemulsifying fenofibrate compositions
WO2009112558A3 (en) Composition comprising pure aloe and its use as a cosmetic base

Legal Events

Date Code Title Description
FA Abandonment or withdrawal